Janux Therapeutics Inc Market Cap ($878.78 Million)
Market Cap & Net Worth: Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc market cap. Janux Therapeutics Inc (NASDAQ:JANX) has a market capitalization of $878.78 Million ($878.78 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9086 globally and #2594 in its home market, demonstrating a 2.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Janux Therapeutics Inc's stock price $17.47 by its total outstanding shares 60984354 (60.98 Million). Also see Janux Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Janux Therapeutics Inc Market Cap History (2021–2026)
Janux Therapeutics Inc market cap history from 2021 to 2026. Data shows change from $1.20 Billion to $1.07 Billion (-6.54% CAGR). Check Janux Therapeutics Inc (JANX) stock price for real-time trading data and today's change.
Index Memberships
Janux Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #262 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #975 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.05% | #153 of 263 |
Weight: Janux Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Janux Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Janux Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore JANX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
84.16x
Janux Therapeutics Inc's market cap is 84.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.20 Billion | $3.64 Million | -$32.56 Million | 330.83x | N/A |
| 2022 | $803.16 Million | $8.61 Million | -$54.15 Million | 93.26x | N/A |
| 2023 | $654.36 Million | $8.08 Million | -$58.29 Million | 80.96x | N/A |
| 2024 | $3.27 Billion | $10.59 Million | -$68.99 Million | 308.38x | N/A |
| 2025 | $841.58 Million | $10.00 Million | -$113.62 Million | 84.16x | N/A |
Competitor Companies of JANX by Market Capitalization
Companies near Janux Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see Janux Therapeutics Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Janux Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Janux Therapeutics Inc (2021–2026)
Market capitalization of Janux Therapeutics Inc from 2021 to today. Between 2021 and today, Janux Therapeutics Inc's market cap moved from $1.20 Billion to $ 1.07 Billion, with a yearly change of -6.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.07 Billion | +26.59% |
| 2025 | $841.58 Million | -74.22% |
| 2024 | $3.27 Billion | +398.97% |
| 2023 | $654.36 Million | -18.53% |
| 2022 | $803.16 Million | -33.25% |
| 2021 | $1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Janux Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $878.78 Million USD |
| MoneyControl | $878.78 Million USD |
| MarketWatch | $878.78 Million USD |
| marketcap.company | $878.78 Million USD |
| Reuters | $878.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more